Trial Profile
A Prospective, Open-Label, Single-Arm Clinical Trial to Assess the Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety of a Single Intramuscular Dose of a Polyvalent Human Immune Globulin in HAV Seronegative Healthy Subjects
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Hepatitis A
- Focus Pharmacodynamics
- Acronyms GamaSTAN
- Sponsors Grifols
- 16 Apr 2020 Results published in the Advances in Therapy
- 21 Sep 2018 Status changed from active, no longer recruiting to completed.
- 04 May 2018 Planned End Date changed from 1 Aug 2018 to 1 Jul 2018.